ESGCT 2025 | Viralgen Aava Platform

At #ESGCT2025, Anna Dirienzo, Global Director of Marketing and Communications at Viralgen, shared an inside look at Aava – the company’s platform for AAV-based gene therapy manufacturing. In just three minutes, she walked through Aava’s two forms, Gen 2.0 (Mendi) and Gen 3.0 (Ituri), and how they’ve helped Viralgen clients reach a 100% success rate in IND/IMPD submissions.

Catch the full conversation with Anna and Aaron to see how Aava is shaping the future of gene therapy manufacturing.